

list Seq/Gen 1646

PATENT
ATTORNEY DOCKET NUMBER: 50128/002002

Certificate of Mailing: Date of Deposit: 10/14/99
I hereby certify under 37 CFR 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.
Colleen Coyne Colleen Coyne
Printed name of person mailing correspondence Signature of person mailing correspondence

#11
11/3/99
Mullu

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Wolfe et al. Art Unit: 1646
Serial No.: 08/984,476 Examiner: Romeo
Filed: December 3, 1997
Title: SPECIFIC ANTAGONISTS FOR GLUCOSE-DEPENDENT
INSULINOTROPIC POLYPEPTIDE (GIP)

RECEIVED
TECH CENTER 1500/2900
99 OCT 22 PM 12:06

Assistant Commissioner of Patents
Washington, D.C. 20231

STATEMENT UNDER 37 CFR §1.825

In reply to the Notice to Comply mailed June 23, 1999 and as required by 37 CFR 1.825(a), enclosed is an substitute sequence listing consisting of four sheets to be inserted at the end of the application.

The amendments correct the formatting errors in the initial sequence listing. I hereby submit that the substitute sheets contain no new matter.

As required by 37 CFR 1.825(b), enclosed is a diskette containing a copy of the sequence listing in computer readable form including all previously submitted data with the amendments incorporated therein. The contents of the computer readable form are the same as the contents of the paper sheets.


If there are any charges, or any credits, please apply them to Deposit Account No.

03-2095.

Respectfully submitted,

Date:

Oct. 14, 1999



Paul T. Clark

Reg. No. 30,162

Clark & Elbing LLP

176 Federal Street


Boston, MA 02110

Telephone: 617-428-0200

Facsimile: 617-428-7045

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE